Literature DB >> 24206272

The membrane proximal region of the cannabinoid receptor CB1 N-terminus can allosterically modulate ligand affinity.

Jonathan F Fay1, David L Farrens.   

Abstract

The human cannabinoid receptor, CB1, a G protein-coupled receptor (GPCR), contains a relatively long (∼110 a.a.) amino terminus, whose function is still not defined. Here we explore a potential role for the CB1 N-terminus in modulating ligand binding to the receptor. Although most of the CB1 N-terminus is not necessary for ligand binding, previous studies have found that mutations introduced into its conserved membrane proximal region (MPR) do impair the receptors ability to bind ligand. Moreover, within the highly conserved MPR (∼ residues 90-110) lie two cysteine residues that are invariant in all CB1 receptors. We find these two cysteines (C98 and C107) form a disulfide in heterologously expressed human CB1, and this C98-C107 disulfide is much more accessible to reducing agents than the previously known disulfide in extracellular loop 2 (EL2). Interestingly, the presence of the C98-C107 disulfide modulates ligand binding to the receptor in a way that can be quantitatively analyzed by an allosteric model. The C98-C107 disulfide also alters the effects of allosteric ligands for CB1, Org 27569 and PSNCBAM-1. Together, these results provide new insights into how the N-terminal MPR and EL2 act together to influence the high-affinity orthosteric ligand binding site in CB1 and suggest that the CB1 N-terminal MPR may be an area through which allosteric modulators can act.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24206272      PMCID: PMC3938390          DOI: 10.1021/bi400842k

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  40 in total

Review 1.  Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors.

Authors:  Patricia H Reggio
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

2.  Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A.

Authors:  D Shire; B Calandra; M Delpech; X Dumont; M Kaghad; G Le Fur; D Caput; P Ferrara
Journal:  J Biol Chem       Date:  1996-03-22       Impact factor: 5.157

3.  Disulfide bonds in the extracellular calcium-polyvalent cation-sensing receptor correlate with dimer formation and its response to divalent cations in vitro.

Authors:  D T Ward; E M Brown; H W Harris
Journal:  J Biol Chem       Date:  1998-06-05       Impact factor: 5.157

4.  Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity.

Authors:  C Blanpain; B Lee; J Vakili; B J Doranz; C Govaerts; I Migeotte; M Sharron; V Dupriez; G Vassart; R W Doms; M Parmentier
Journal:  J Biol Chem       Date:  1999-07-02       Impact factor: 5.157

5.  Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons.

Authors:  W Twitchell; S Brown; K Mackie
Journal:  J Neurophysiol       Date:  1997-07       Impact factor: 2.714

6.  Determination and characterization of a cannabinoid receptor in rat brain.

Authors:  W A Devane; F A Dysarz; M R Johnson; L S Melvin; A C Howlett
Journal:  Mol Pharmacol       Date:  1988-11       Impact factor: 4.436

7.  Metabotropic glutamate receptor 5 is a disulfide-linked dimer.

Authors:  C Romano; W L Yang; K L O'Malley
Journal:  J Biol Chem       Date:  1996-11-08       Impact factor: 5.157

8.  Control of pain initiation by endogenous cannabinoids.

Authors:  A Calignano; G La Rana; A Giuffrida; D Piomelli
Journal:  Nature       Date:  1998-07-16       Impact factor: 49.962

9.  Membrane assembly of the cannabinoid receptor 1: impact of a long N-terminal tail.

Authors:  Helena Andersson; Aaron M D'Antona; Debra A Kendall; Gunnar Von Heijne; Chen-Ni Chin
Journal:  Mol Pharmacol       Date:  2003-09       Impact factor: 4.436

10.  Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process.

Authors:  S A Deadwyler; R E Hampson; J Mu; A Whyte; S Childers
Journal:  J Pharmacol Exp Ther       Date:  1995-05       Impact factor: 4.030

View more
  17 in total

1.  Structural dynamics and energetics underlying allosteric inactivation of the cannabinoid receptor CB1.

Authors:  Jonathan F Fay; David L Farrens
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-22       Impact factor: 11.205

Review 2.  Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.

Authors:  Leepakshi Khurana; Ken Mackie; Daniele Piomelli; Debra A Kendall
Journal:  Neuropharmacology       Date:  2017-05-17       Impact factor: 5.250

3.  Molecular-interaction and signaling profiles of AM3677, a novel covalent agonist selective for the cannabinoid 1 receptor.

Authors:  David R Janero; Suma Yaddanapudi; Nikolai Zvonok; Kumar V Subramanian; Vidyanand G Shukla; Edward Stahl; Lei Zhou; Dow Hurst; James Wager-Miller; Laura M Bohn; Patricia H Reggio; Ken Mackie; Alexandros Makriyannis
Journal:  ACS Chem Neurosci       Date:  2015-05-29       Impact factor: 4.418

4.  Dynamic roles for the N-terminus of the yeast G protein-coupled receptor Ste2p.

Authors:  M Seraj Uddin; Fred Naider; Jeffrey M Becker
Journal:  Biochim Biophys Acta Biomembr       Date:  2017-07-25       Impact factor: 3.747

Review 5.  Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.

Authors:  Thuy Nguyen; Jun-Xu Li; Brian F Thomas; Jenny L Wiley; Terry P Kenakin; Yanan Zhang
Journal:  Med Res Rev       Date:  2016-11-23       Impact factor: 12.944

6.  Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.

Authors:  Mylyne Tham; Orhan Yilmaz; Mariam Alaverdashvili; Melanie E M Kelly; Eileen M Denovan-Wright; Robert B Laprairie
Journal:  Br J Pharmacol       Date:  2018-08-10       Impact factor: 8.739

7.  Crystal Structure of the Human Cannabinoid Receptor CB1.

Authors:  Tian Hua; Kiran Vemuri; Mengchen Pu; Lu Qu; Gye Won Han; Yiran Wu; Suwen Zhao; Wenqing Shui; Shanshan Li; Anisha Korde; Robert B Laprairie; Edward L Stahl; Jo-Hao Ho; Nikolai Zvonok; Han Zhou; Irina Kufareva; Beili Wu; Qiang Zhao; Michael A Hanson; Laura M Bohn; Alexandros Makriyannis; Raymond C Stevens; Zhi-Jie Liu
Journal:  Cell       Date:  2016-10-20       Impact factor: 41.582

Review 8.  Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity.

Authors:  Rachel Dopart; Dai Lu; Aron H Lichtman; Debra A Kendall
Journal:  Drug Metab Rev       Date:  2018-01-21       Impact factor: 4.518

Review 9.  Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target.

Authors:  David R Janero; Ganesh A Thakur
Journal:  Expert Opin Drug Discov       Date:  2016-10-21       Impact factor: 6.098

10.  Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor.

Authors:  R B Laprairie; A M Bagher; M E M Kelly; E M Denovan-Wright
Journal:  Br J Pharmacol       Date:  2015-10-13       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.